These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32139432)

  • 1. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
    Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
    Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
    Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
    Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
    Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
    Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
    Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
    Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.
    Gu L; Zhou C; Liu H; Gao J; Li Q; Mu D; Ma Z
    J Exp Clin Cancer Res; 2010 Nov; 29(1):150. PubMed ID: 21083937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells.
    Kullmann MK; Grubbauer C; Goetsch K; Jäkel H; Podmirseg SR; Trockenbacher A; Ploner C; Cato AC; Weiss C; Kofler R; Hengst L
    Cell Cycle; 2013 Aug; 12(16):2625-35. PubMed ID: 23907123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
    Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
    Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel method to establish glucocorticoid resistant acute lymphoblastic leukemia cell lines.
    Gu L; Zhang G; Zhang Y
    J Exp Clin Cancer Res; 2019 Jun; 38(1):269. PubMed ID: 31221196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia.
    Hui PY; Chen YH; Qin J; Jiang XH
    Hematology; 2022 Dec; 27(1):32-42. PubMed ID: 34957927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.
    Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
    Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
    Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
    Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia.
    Sarno J; Domizi P; Liu Y; Merchant M; Pedersen CB; Jedoui D; Jager A; Nolan GP; Gaipa G; Bendall SC; Bava FA; Davis KL
    Nat Commun; 2023 May; 14(1):2935. PubMed ID: 37217509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.
    Silic-Benussi M; Sharova E; Ciccarese F; Cavallari I; Raimondi V; Urso L; Corradin A; Kotler H; Scattolin G; Buldini B; Francescato S; Basso G; Minuzzo SA; Indraccolo S; D'Agostino DM; Ciminale V
    Redox Biol; 2022 May; 51():102268. PubMed ID: 35248829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hypoxia on proliferation and glucocorticoid resistance of T-cell acute lymphoblastic leukaemia.
    Li Y; Wei Y; Gu L
    Hematology; 2021 Dec; 26(1):775-784. PubMed ID: 34565306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
    Roderick JE; Gallagher KM; Murphy LC; O'Connor KW; Tang K; Zhang B; Brehm MA; Greiner DL; Yu J; Zhu LJ; Green MR; Kelliher MA
    Blood; 2021 Jan; 137(4):500-512. PubMed ID: 33507291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B.
    Gong H; Liu L; Cui L; Ma H; Shen L
    Mol Carcinog; 2021 Sep; 60(9):644-657. PubMed ID: 34169564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
    Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
    Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
    Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.